skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Proton Radiation Therapy for the Treatment of Retinoblastoma

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1]; ; ; ; ; ; ; ;  [2];  [3];  [4]
  1. Harvard Radiation Oncology Program, Boston, Massachusetts (United States)
  2. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts (United States)
  3. Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts (United States)
  4. Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts (United States)

Purpose: To investigate long-term disease and toxicity outcomes for pediatric retinoblastoma patients treated with proton radiation therapy (PRT). Methods and Materials: This is a retrospective analysis of 49 retinoblastoma patients (60 eyes) treated with PRT between 1986 and 2012. Results: The majority (84%) of patients had bilateral disease, and nearly half (45%) had received prior chemotherapy. At a median follow-up of 8 years (range, 1-24 years), no patients died of retinoblastoma or developed metastatic disease. The post-PRT enucleation rate was low (18%), especially in patients with early-stage disease (11% for patients with International Classification for Intraocular Retinoblastoma [ICIR] stage A-B disease vs 23% for patients with ICIR stage C-D disease). Post-PRT ophthalmologic follow-up was available for 61% of the preserved eyes (30 of 49): 14 of 30 eyes (47%) had 20/40 visual acuity or better, 7 of 30 (23%) had moderate visual acuity (20/40-20/600), and 9 of 30 (30%) had little or no useful vision (worse than 20/600). Twelve of 60 treated eyes (20%) experienced a post-PRT event requiring intervention, with cataracts the most common (4 eyes). No patients developed an in-field second malignancy. Conclusions: Long-term follow-up of retinoblastoma patients treated with PRT demonstrates that PRT can achieve high local control rates, even in advanced cases, and many patients retain useful vision in the treated eye. Treatment-related ocular side effects were uncommon, and no radiation-associated malignancies were observed.

OSTI ID:
22420475
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 90, Issue 4; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Results of high dose 106-ruthenium irradiation of choroidal melanomas
Journal Article · Wed Oct 01 00:00:00 EDT 1986 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:22420475

External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis
Journal Article · Wed Mar 01 00:00:00 EST 1989 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:22420475

Cataract extraction after brachytherapy for malignant melanoma of the choroid
Journal Article · Wed May 01 00:00:00 EDT 1991 · Ophthalmology (Rochester, Minnesota); (United States) · OSTI ID:22420475